Navigation Links
Hologic Announces Fourth Quarter and Fiscal 2010 Operating Results
Date:11/8/2010

tyle="font-family:Arial;font-size:8pt;">263,000

(5)Explanatory Notes:(1) To exclude the anticipated on-going, non-cash amortization of intangible assets.

(2) To exclude the anticipated additional non-cash interest expense relating to the Company's convertible debt.

(3) To exclude the anticipated change to contingent consideration relating to the Company’s acquisitions.

(4) To reflect an estimated annual effective tax rate of 35% for the first quarter and full year of fiscal 2011 on a non-GAAP basis.

(5) We expect estimated diluted weighted average shares outstanding of 263,000 for the first quarter and full year of fiscal 2011.Use of Non-GAAP Financial Measures: The Company has presented the following non-GAAP financial measures in this press release: adjusted net income; adjusted EPS; and adjusted EBITDA. The Company defines its non-GAAP adjusted net income to exclude the non-cash amortization of intangible assets and impairment of goodwill and intangible assets, other acquisition-related charges, such as change in contingent consideration, transaction costs, charges associated with the write-off of acquired in-process research and development and the write-up of acquired inventory to fair value, non-cash charges resulting from changes in GAAP, closure and restructuring charges, and one-time, nonrecurring, unusual or unanticipated charges, expenses or gains. As set forth in the applicable reconciliation tables above, non-GAAP adjusted net income and non-GAAP adjusted EPS for the periods presented exclude the following items from GAAP net (loss) income and EPS: (i) non-cash expenses associated with the Company's recent acquisitions, including amortization of intangible assets and the write-off of goodwill and intangible assets; (ii) non-cash interest expense resulting from the Company's adoption of a new standard under GAAP that changed the accounting for convertible debt instruments with cash settlement features; (ii
'/>"/>

SOURCE Hologic, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related medicine technology :

1. Hologic Announces Long-term, Five-year Results from MammoSite® ASBS Registry Study
2. Hologic to Host Investor Presentation at RSNA 2010
3. Hologic to Release Fourth Quarter Fiscal 2010 Operating Results on Monday, November 8, 2010
4. Hologics Selenia Dimensions (3-D) Digital Mammography Tomosynthesis System Receives Favorable Votes From FDA Advisory Panel
5. Hologic to Present at the 2010 Morgan Stanley Global Healthcare Conference
6. Ethicon Endo-Surgery Announces Agreement with Hologic Inc. To Resolve Patent Disputes
7. Hologic Announces Decision in Patent Infringement Suit
8. Bayer HealthCare Pharmaceuticals Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimers Disease
9. New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity
10. Hologic to Feature Adiana(R) Permanent Contraception System at AAGL 2009
11. Hologic to Present at NASDAQ OMX 23rd Investor Program in London
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014  RESMED INC. (NYSE: RMD ... and fiscal year ended June 30, 2014 results on Thursday, ... close. A press release with ResMed,s results will be issued ... host a webcast to discuss operating results and future outlook. ... 1:30 p.m. US Pacific Time and the live webcast of ...
(Date:7/10/2014)...  BC Technical, the largest nationwide, non-OEM provider of ... a leading provider of Siemens Nuclear Medicine and Molecular ... BC Technical as the authorized provider of service and ... BC Technical announced today that the two companies have ... the service and systems provider for MiE,s camera systems. ...
(Date:7/10/2014)... , July 10, 2014   Ventana Medical Systems, ... announced it has entered into an agreement with Merck ... as EMD Serono in the United States ... collaborate with Merck KGaA,s biopharmaceutical division on the development ... undisclosed target using Ventana,s proprietary diagnostic assays. In alignment ...
Breaking Medicine Technology:ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... Oct. 17, 2011 Archimedes Pharma Ltd., and its ... (fentanyl) nasal spray is now available by prescription in ... breakthrough pain in cancer patients 18 years of age ... tolerant to opioid therapy for their underlying persistent cancer ...
... Calif., Oct. 17, 2011 Abaxis, Inc. (NasdaqGS: ABAX), a ... a conference call to discuss its financial results for the ... The call will be at 4:15 p.m. ET on Tuesday, ... the second quarter of fiscal year 2012 after the market ...
Cached Medicine Technology:Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 2Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 3Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 4Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 5Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 6Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 7Abaxis to Report Second Quarter Fiscal Year 2012 Financial Results Tuesday, October 25, 2011 2
(Date:7/10/2014)... 10, 2014 Ivalua, the global ... of the 4th “Trending in Procurement” report on ... , Every day multinational corporations process thousands of ... etc. To meet this challenge, more and more ... can be defined as a suite of integrated ...
(Date:7/10/2014)... Most professional football players who have shoulder stabilization surgery ... study finds. Shoulder instability is a common injury ... surgery to fix the problem has been unclear, the ... players who had shoulder stabilization surgery. Ninety percent of ... defined as playing in at least one regular season ...
(Date:7/10/2014)... who have a vasectomy may be at increased risk ... But the risk is comparatively small, the researchers acknowledged. ... more research is needed to determine if the study ... researchers analyzed data from more than 49,400 American men ... During that time, 6,023 cases of prostate cancer were ...
(Date:7/10/2014)... Medical Service (EMS) responders felt better prepared to respond ... training according to a new study in the journal ... first study to specifically examine the EMS provider comfort ... shooter has not yet been neutralized or working with ... as the Columbine High School shooting, the Virginia Tech ...
(Date:7/10/2014)... obesity is one of the top public health concerns ... aged 2-19 classified as obese as of 2012. As ... organizations have taken to Twitter to discuss the problem. ... PhD, assistant professor at the Brown School at Washington ... hashtag #childhoodobesity in tweets to track Twitter conversations about ...
Breaking Medicine News(10 mins):Health News:‘Source-to-Pay’ e-Procurement Is Real Performance Driver for Purchasing Departments 2Health News:‘Source-to-Pay’ e-Procurement Is Real Performance Driver for Purchasing Departments 3Health News:Shoulder Surgery Gets NFL Players Back in the Game 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 3Health News:Active shooter training increases comfort level of emergency responders 2Health News:Study looks at how Twitter can be used to address specific health issues 2
... due to non-recurring event in 2007, net loss stable ... Canadian dollars unless otherwise noted), BELLEVILLE, ON, Nov. ... research-based, technology-driven Canadian,biopharmaceutical company, today announced financial results for ... 30, 2007. "We are also focused on the ...
... Reduce Debt and Enhance Financial Flexibility To Fund ... ... Balance, Inc.,(Nasdaq: SMBL ) today announced its results for the third ... 2007, the Company,reported net sales of approximately $42 million and a net ...
... HALL, N.C., EXTON, Pa. and SAN DIEGO, Nov. ... southeastern US,provider of oncology equipment sales and service, ... alliance with Radiology Oncology Systems, Inc.,(ROS), an oncology ... Acceletronics, Inc., a US provider of oncology equipment ...
... and ... Product Portfolio, LA JOLLA, Calif., ... today announced that,it has raised $33.9 million in a Series B ... round were Frazier,Healthcare Ventures and Alloy Ventures, along with founding investor ...
... Charged with Illegally Distributing over 12 Million Narcotic ... United States,Attorney Matt M. Dummermuth announced today that ... distribute controlled substances through an,Internet pharmacy and with ... in an Indictment filed today in United States ...
... Nov. 8 Cash Technologies, Inc.,(Amex: TQ ) ... American,Stock Exchange (the "Exchange" or "AMEX") notified Cash Tech ... certain of the Exchange,s continued,listing standards as set forth ... Guide). Specifically, Cash Tech is not in compliance with ...
Cached Medicine News:Health News:Bioniche Reports Fiscal 2008 First Quarter 2Health News:Bioniche Reports Fiscal 2008 First Quarter 3Health News:Bioniche Reports Fiscal 2008 First Quarter 4Health News:Bioniche Reports Fiscal 2008 First Quarter 5Health News:Bioniche Reports Fiscal 2008 First Quarter 6Health News:Bioniche Reports Fiscal 2008 First Quarter 7Health News:Bioniche Reports Fiscal 2008 First Quarter 8Health News:Bioniche Reports Fiscal 2008 First Quarter 9Health News:Bioniche Reports Fiscal 2008 First Quarter 10Health News:Bioniche Reports Fiscal 2008 First Quarter 11Health News:Smart Balance Announces Third Quarter 2007 Results 2Health News:Smart Balance Announces Third Quarter 2007 Results 3Health News:Smart Balance Announces Third Quarter 2007 Results 4Health News:Smart Balance Announces Third Quarter 2007 Results 5Health News:Smart Balance Announces Third Quarter 2007 Results 6Health News:Smart Balance Announces Third Quarter 2007 Results 7Health News:Smart Balance Announces Third Quarter 2007 Results 8Health News:Smart Balance Announces Third Quarter 2007 Results 9Health News:Smart Balance Announces Third Quarter 2007 Results 10Health News:Smart Balance Announces Third Quarter 2007 Results 11Health News:RS&A, Inc. Announces It Has Joined Radiology Oncology Systems, Inc. (ROS) and Acceletronics, Inc. in a Strategic Alliance to Better Serve Its Customers in the Southeastern US 2Health News:RS&A, Inc. Announces It Has Joined Radiology Oncology Systems, Inc. (ROS) and Acceletronics, Inc. in a Strategic Alliance to Better Serve Its Customers in the Southeastern US 3Health News:Anaptys Biosciences Raises Over $33 Million in Series B Financing 2Health News:Anaptys Biosciences Raises Over $33 Million in Series B Financing 3Health News:$40 Million Forfeiture Sought in Nation-Wide Internet Pharmacy Case 2Health News:Cash Technologies Discusses AMEX Listing Requirements 2Health News:Cash Technologies Discusses AMEX Listing Requirements 3Health News:Cash Technologies Discusses AMEX Listing Requirements 4
The Trident PSL Acetabular Shells are designed to maximize fixation in the peripheral lunate region of the acetabulum....
... has been designed to enhance fixation in ... hole configurations. The objective of the product ... primary modes: Tilt, migration and rotation. The ... initial and long-term fixation. The porous coating ...
The Biopro All Poly cup is a uniquely designed UHMWPE acetabular cup....
The MPF cup is specifically designed to achieve high primary stability, a critical factor for long term success....
Medicine Products: